Kevin M. Brennan
SVP, FINANCE AND ACCOUNTING · Xilio Therapeutics, Inc.
- 2024
- Jan 5, 2026
- 3
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Kevin M. Brennan files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- GILEAD SCIENCES, INC. - $2.00M in XLO purchases and sales in the last 12 months
- James Samuel Shannon - $44K in XLO purchases and sales in the last 12 months
- Christopher James Frankenfield - $5K in XLO purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Kevin M. Brennan?
Kevin M. Brennan is a corporate insider, tracked as SVP, FINANCE AND ACCOUNTING of Xilio Therapeutics, Inc. (XLO). InsiderAlpha holds 3 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did Kevin M. Brennan last file a Form 4?
The most recent primary Form 4 on record is dated 5 January 2026, one of 3 filings going back to 2024.
Has Kevin M. Brennan been buying or selling stock?
Recorded transactions: 0 open-market purchases and 1 open-market sale ($1K) across all tracked filings.
